Evaluation of Clinicopathologic and Prognostic Significance of nm23 protein in stage III Gastric Adenocarcinoma.
- Author:
Dong Ho HAN
1
;
Hyung Tae OH
;
Duk Su LEE
;
Sang Young KIM
;
Byung Yi AHN
;
Myung Jin JOO
;
Kwang Min LEE
;
Jong Myung LEE
;
Sung Hye SHIN
;
Min Chul KIM
Author Information
1. Department of Hemato-Oncology, Presbyterian Medical Center, Jeon Ju.
- Publication Type:Original Article
- Keywords:
stage III gastric adenocarcinoma;
nm23 protein
- MeSH:
Adenocarcinoma*;
Breast Neoplasms;
Carcinoma, Hepatocellular;
Colonic Neoplasms;
Disease Progression;
Down-Regulation;
Gene Expression;
Melanoma;
Neoplasm Metastasis;
Stomach Neoplasms;
Survival Rate
- From:Korean Journal of Medicine
1998;55(5):868-873
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Gene expression of nm23 has been investigated in a number of tumors, including breast cancer, colon cancer, malignant melanoma, and hepatocellular carcinoma. Its down-regulation has been shown to be associated with metastasis or disease progression in some of the tumors. This study was carried out to define the relationship between nm23 protein expression and clinicopathological variables. METHODS: nm23 protein levels were investigated in 64 surgically resected specimens of stage III gastric cancer by immunohistochemical method, and association with clinicopathological parameters and survival rates were determined. RESULTS: The overall expression rates of nm23 was 68.7 %. There was no significant difference between nm23 protein expression and clinicopathological variables such as age, sex, stage, histology, tumor depth, number of metastatic nodes, tumor size, site and method of operation. Statistically, no significant differences between nm23 protein expression and overall survival rates were found. CONCLUSIONS: These results suggest that nm23 protein expression is an unsatisfactory prognostic indicator in stage III gastric adenocarcinoma.
